文献速递生殖医学

国际辅助生殖技术监测委员会世界报告:2012年辅助生殖技术

International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology 2012†.
PubMed 文献 · Hum Reprod · 2020-01-01

该报告为国际辅助生殖技术监测委员会(ICMART)2012年全球辅助生殖技术(ART)回顾性横断面调查,69个国家2600家诊所报告了1,149,817个周期,估算缺失后为1,948,898个周期,较2011年增加18.6%,活产儿>465,286例(+17.9%),中国未报告。冻胚移植、卵母细胞捐赠、植入前遗传学检测和单胚胎移植增加,妊娠率和分娩率稳定,多胎分娩减少。

要点

  • 2012年报告ART周期1,149,817个,估算后1,948,898个,较2011年增加18.6%。
  • 新鲜非供卵周期单胚胎移植比例从2011年31.4%升至2012年33.7%。
  • 新鲜非供卵双胎分娩率从19.6%降至18.0%,三胎率从0.9%降至0.8%。

核心结论

  • 2012年全球ART周期数较2011年增加近20%,冻胚移植、卵母细胞捐赠、植入前遗传学检测和单胚胎移植增加,妊娠率和分娩率稳定,多胎分娩减少。

研究设计与样本

  • 回顾性横断面调查,69个国家和2600家ART诊所通过国家和区域ART登记处提交2012年ART周期及妊娠结局数据。

主要发现

  • 报告1,149,817个ART周期,估算缺失后为1,948,898个周期,较2011年增加18.6%,活产儿>465,286例(+17.9%),中国未报告。
  • 2011年至2012年,报告的取卵周期和冻胚移植周期分别增加6.9%和16.0%。
  • 接受非供卵ART的女性中40岁及以上比例从2011年24.0%升至2012年25.2%,ICSI占非供卵取卵周期比例从66.5%升至68.9%。
  • 新鲜取卵周期和冻胚移植周期的IVF/ICSI合并分娩率分别为19.8%和22.1%。
  • 新鲜非供卵周期单胚胎移植从2011年31.4%升至2012年33.7%,平均移植胚胎数从1.91降至1.88;冻胚移植非供卵周期单胚胎移植为54.8%,平均移植1.54个胚胎。

关键数值与推荐

  • 新鲜非供卵双胎分娩率从2011年19.6%降至2012年18.0%,三胎率从0.9%降至0.8%;冻胚移植非供卵周期双胎率和三胎率分别为11.1%和0.4%。
  • 每取卵周期累计分娩率从2011年28.0%升至2012年28.9%。
  • 新鲜IVF/ICSI每1000例出生围产期死亡率为21.4,冻胚移植后为15.9。
  • ICMART世界报告提供ART利用、有效性、安全性和质量的全球统计普查和综述。
  • 随着单胚胎移植和全胚冷冻增加及冻胚移植比例增加,新鲜周期每取卵周期妊娠率和分娩率不能准确估计ART效率,应使用每取卵周期累计活产率并结合相关新鲜周期结局,并需就此达成全球共识。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据取决于各国直接或通过区域登记处提交给ICMART的数据质量和完整性。
  • 本报告覆盖约三分之二的世界ART活动,主要缺失国家为中国。
  • 仍需持续努力改进登记处报告ART数据的质量和一致性,包括使用国际公认的标准定义(国际不孕与生育保健术语表)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What was the utilization, effectiveness and safety of practices in ART globally in 2012 and what global trends could be observed? SUMMARY ANSWER: The total number of ART cycles increased by almost 20% since 2011 and the main trends were an increase in frozen embryo transfers (FET), oocyte donation, preimplantation genetic testing and single embryo transfers (SET), whereas pregnancy and delivery rates (PR, DR) remained stable, and multiple deliveries decreased. WHAT IS KNOWN ALREADY: ART is widely practiced throughout the world, but continues to be characterized by significant disparities in utilization, availability, practice, effectiveness and safety. The International Committee for Monitoring Assisted Reproductive Technologies (ICMART) annual world report provides a major tool for tracking trends in ART treatment for over 25 years and gives important data to ART professionals, public health authorities, patients and the general public. STUDY DESIGN, SIZE, DURATION: A retrospective, cross-sectional survey on the utilization, effectiveness and safety of ART procedures performed globally during 2012 was carried out. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sixty-nine countries and 2600 ART clinics submitted data on ART cycles performed during the year 2012, and their pregnancy outcome, through national and regional ART registries. ART cycles and outcomes are described at country, regional and global levels. Aggregate country data were processed and analyzed based on methods developed by ICMART. MAIN RESULTS AND ROLE OF CHANCE: A total of 1 149 817 ART cycles were reported for the treatment year 2012. After imputing data for missing values and non-reporting clinics in reporting countries, 1 948 898 cycles (an increase of 18.6% from 2011) resulted in >465 286 babies (+17.9%) in reporting countries. China did not report and is not included in this estimate. The best estimate of global utilization including China is ∼2.8 million cycles and 0.9 million babies. From 2011 to 2012, the number of reported aspirations and FET cycles increased by 6.9% and 16.0%, respectively. The proportion of women aged 40 years or older undergoing non-donor ART increased from 24.0% in 2011 to 25.2% in 2012. ICSI, as a percentage of non-donor aspiration cycles, increased from 66.5% in 2011 to 68.9% in 2012. The IVF/ICSI combined delivery rates per fresh aspiration and FET cycles were 19.8% and 22.1%, respectively. In fresh non-donor cycles, SET increased from 31.4% in 2011 to 33.7% in 2012, while the average number of transferred embryos decreased from 1.91 to 1.88, respectively-but with wide country variation. The rates of twin deliveries following fresh non-donor transfers decreased from 19.6% in 2011 to 18.0% in 2012, and the triplet rate decreased from 0.9% to 0.8%. In FET non-donor cycles, SET was 54.8%, with an average of 1.54 embryos transferred and twin and triplet rates of 11.1% and 0.4%, respectively. The cumulative DR per aspiration increased from 28.0% in 2011 to 28.9% in 2012. The overall perinatal mortality rate per 1000 births was 21.4 following fresh IVF/ICSI and 15.9 per 1000 following FET. LIMITATIONS, REASONS FOR CAUTION: The data presented depend on the quality and completeness of data submitted by individual countries to ICMART directly or through regional registries. This report covers approximately two-thirds of` world ART activity, with a major missing country, China. Continued efforts to improve the quality and consistency of reporting ART data by registries are still needed, including the use of internationally agreed standard definitions (International Glossary of Infertility and Fertility Care). WIDER IMPLICATIONS OF THE FINDINGS: The ICMART world reports provide the most comprehensive global statistical census and review of ART utilization, effectiveness, safety and quality. While ART treatment continues to increase globally, the wide disparities in access to treatment, procedures performed and embryo transfer practices warrant attention by clinicians and policy makers. With the increasing practice of SET and of freeze all and resulting increased proportion of FET cycles, it is clear that PR and DR per aspiration in fresh cycles do not give an overall accurate estimation of ART efficiency. It is time to use cumulative live birth rate per aspiration, combining the outcomes of FET cycles with the associated fresh cycle from which the embryos were obtained, and to obtain global consensus on this approach. STUDY FUNDING/COMPETING INTEREST(S): The authors declare no conflict of interest and no specific support from any organizations in relation to this manuscript. ICMART gratefully acknowledges financial support from the following organizations: American Society for Reproductive Medicine; European Society for Human Reproduction and Embryology; Fertility Society of Australia; Japan Society for Reproductive Medicine; Japan Society of Fertilization and Implantation; Red Latinoamericana de Reproduccion Asistida; Society for Assisted Reproductive Technology; Ferring Pharmaceuticals and Abbott (both providing ICMART unrestricted grants unrelated to world reports). TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. de Mouzon J, Chambers GM, Zegers-Hochschild F, et al. International Committee for Monitoring Assisted Reproductive Technologies world report: assisted reproductive technology 2012†. Hum Reprod. 2020. PMID: 32699900. doi:10.1093/humrep/deaa090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。